What is Leerink Partnrs’ Forecast for VRTX Q1 Earnings?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Vertex Pharmaceuticals in a research note issued on Monday, February 10th. Leerink Partnrs analyst D. Risinger anticipates that the pharmaceutical company will post earnings of $3.50 per share for the quarter. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.94) per share. Leerink Partnrs also issued estimates for Vertex Pharmaceuticals’ Q3 2025 earnings at $4.23 EPS and Q4 2025 earnings at $4.81 EPS.

Other equities research analysts also recently issued reports about the stock. Barclays raised their target price on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an “equal weight” rating in a research note on Tuesday. Royal Bank of Canada raised their price objective on shares of Vertex Pharmaceuticals from $402.00 to $407.00 and gave the company a “sector perform” rating in a research report on Tuesday. Citigroup assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 14th. They issued a “buy” rating and a $575.00 target price for the company. Bank of America lowered their price target on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research report on Thursday, December 19th. Finally, StockNews.com cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. Ten analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $505.96.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $453.20 on Thursday. The firm has a market capitalization of $116.71 billion, a P/E ratio of -227.74, a P/E/G ratio of 1.80 and a beta of 0.41. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The stock’s 50-day simple moving average is $435.70 and its two-hundred day simple moving average is $461.79. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%.

Insiders Place Their Bets

In related news, EVP Ourania Tatsis sold 310 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the sale, the executive vice president now directly owns 64,021 shares in the company, valued at $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.20% of the company’s stock.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRTX. Mutual Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock worth $1,751,000 after acquiring an additional 21 shares in the last quarter. Truvestments Capital LLC increased its stake in shares of Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock valued at $40,000 after purchasing an additional 23 shares in the last quarter. Outlook Wealth Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 2.8% during the third quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock valued at $415,000 after purchasing an additional 24 shares during the last quarter. Dunhill Financial LLC boosted its position in shares of Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares in the last quarter. Finally, Simon Quick Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 1.1% in the 4th quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company’s stock worth $900,000 after buying an additional 24 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.